Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. - Wikidata - wikimedia - TriplyDB

Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease.

Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease.

http://www.wikidata.org/entity/Q40118659

about

Patient perspectives on fluticasone-vilanterol versus other corticosteroid combination products for the treatment of asthma NF-κB and HIF crosstalk in immune responses NF-kappaB Signaling in Chronic Inflammatory Airway Disease Design and x-ray crystal structures of high-potency nonsteroidal glucocorticoid agonists exploiting a novel binding site on the receptor Effects of representative glucocorticoids on TNFα- and CD40L-induced NF-κB activation in sensor cells Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis.Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination.Seasonal allergic rhinitis: fluticasone propionate and fluticasone furoate therapy evaluated Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial.Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma Discovery of a highly potent glucocorticoid for asthma treatment Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/ Formoterol 100/6 μg b.i.d.: a 12-week cost analysis in mild-to-moderate asthma.Intranasal corticosteroids: the development of a drug delivery device for fluticasone furoate as a potential step toward improved compliance.Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma.Therapeutic management of allergic diseases.From pharmacokinetics to therapeutics.Mometasone furoate: an inhaled glucocorticoid for the management of asthma in adults and children.Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma.Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone.Molecular mechanisms of glucocorticoids action: implications for treatment of rhinosinusitis and nasal polyposis.Rational ligand-based virtual screening and structure-activity relationship studies in the ligand-binding domain of the glucocorticoid receptor-α.Fluticasone furoate nasal spray: Profile of an enhanced-affinity corticosteroid in treatment of seasonal allergic rhinitis.A review of the use of fluticasone furoate since its launch.Asthma: beyond corticosteroid treatment.Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease.Fluticasone furoate/vilanterol: a review of its use in patients with asthma.Inhaled corticosteroids: potency, dose equivalence and therapeutic index.Emerging corticosteroid agonists for the treatment of asthma.Fixed-Dose combination of the inhaled corticosteroid and long-acting beta2-agonist therapy in adults with persistent asthma.Vilanterol trifenatate for the treatment of COPD.Pharmacodynamic and pharmacokinetic assessment of fluticasone furoate + vilanterol for the treatment of asthma.Phamacology of fluticasone furoate and vilanterol trifenatate combination therapy for asthma.Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy Contemporary Use of Corticosteroids in Rhinology.Discovery of GW870086: a potent anti-inflammatory steroid with a unique pharmacological profile Fluticasone furoate nasal spray reduces symptoms of uncomplicated acute rhinosinusitis: a randomised placebo-controlled study.Fluticasone furoate and vilanterol trifenatate combination therapy for the treatment of asthma.

P2860

Q26743444-0EF55391-A2F9-4B0D-9F8B-AB84EAEF1CE4 Q26777974-3E6FC022-9C30-4012-A80D-7D21D93A7300 Q27009696-ADF99A22-1F5F-4F9F-A0E3-B46F3D622203 Q27657764-7BBE5958-FE66-44FF-B2FA-4CE04CC9D47F Q33726061-A3900CFE-3E70-42B5-9964-10FB5D62ED3B Q34166101-3FB99DA7-D3F4-4B3B-A6F7-4C49B6F93504 Q34470553-01888026-5633-4015-BDEE-DAEF8259CB95 Q34620179-393FC1DE-5992-4A14-A4B4-7B4BB842D6A6 Q35554841-DB431418-5A4C-4B52-B580-BF1A1E4399DE Q35686996-0C907EAA-0285-49AB-A611-17434BCFE23F Q35766467-DF7BE198-4AC0-4E8B-93C4-6CAD7ECB7B48 Q36769629-1C94616F-A80E-4E19-8B6F-B1479A272CFC Q36970994-DC7ACD6C-4CD6-46F6-BF60-761A31FCD891 Q36985924-1400AAB0-D1F4-45C1-BB68-480E8C7A6DE3 Q37436410-C30C28F0-64A7-4BBC-9428-EAFDF4F3B55C Q37550543-11B23248-97D3-45A5-8488-03A7EA0111E1 Q37550564-195BC68B-3EDB-4609-B1AF-52022CBA173F Q37556510-F03F1722-A476-4894-8C21-56B6B0659F05 Q37610412-865983F4-3FE4-45D9-902D-65FC5F97FE6E Q37614090-51922D8F-7843-4F7A-891E-9EAA4BBB0E4A Q37658668-512E7D93-1E0D-4B11-98F4-F7DDDB64DCD2 Q37772416-2F4EE2B3-2B91-46B1-9CF9-39AA6908A2AE Q37855890-DD1699F8-3A25-4F55-BE3E-FAFA66D1223F Q37857678-BFA29859-CA62-40B6-8D05-619820D2BB79 Q37907340-0AE2B338-576E-4B2E-8D61-D0B9C9F45E41 Q38121086-15542603-A899-4FB0-9821-70B8F33BD9ED Q38164675-CE615086-A08A-4117-BA04-43B4A4530968 Q38235191-D8496CF5-2EBF-4CBF-8E54-D6E7D636457B Q38342870-A02499E6-A100-404B-AF9C-920D31B668D7 Q38390724-A7C50B5E-9E9D-4D1E-9647-43FDC2D90120 Q38537176-BF2E52E7-9762-484C-89E9-93218B7C54E8 Q38707759-5D70F1AB-4600-4695-BC77-4586650C4DA9 Q38824916-73A0E380-6977-402C-AC1F-08CBA57DCA69 Q38851423-C8C6D3ED-A35D-42A7-9B0F-2B55A8B643D0 Q38947467-00D693D6-8E0C-4DCB-85C5-026595520E84 Q39003291-3CB1951E-BEB2-4D46-BB51-899FA8CE3F9E Q39148811-61176EB4-1790-460B-8DB7-3F9224526BF3 Q39157135-399E8BFA-5672-4D52-9D05-DA0E7BA727DD Q39247547-BD97EE27-AAB0-41AB-A793-C72AE6C55611 Q40661319-4A02E5D6-4786-4D10-BAAD-ECC57E159D59

P2860

Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease.

http://www.wikidata.org/entity/Q40118659

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Pharmacological properties of ...... piratory inflammatory disease.

@en

type

label

Pharmacological properties of ...... piratory inflammatory disease.

@en

prefLabel

Pharmacological properties of ...... piratory inflammatory disease.

@en

P1433

Q40118659-8E527D6C-0D10-4EDC-8DB5-E73F6D16C5DD

P1476

Q40118659-B335DCCB-2D2F-4A39-910F-8ADDCB339022

P2093

Q40118659-215B3045-5D33-405D-8806-FA27363102F1

Q40118659-4C6D4D4F-9627-4D53-A539-E61809BD81B2

Q40118659-72D3C6B8-5CC4-4073-9501-614CC2357A85

Q40118659-8AF3282F-05CF-47DF-8BBE-B728395E5E02

Q40118659-8B7D21DC-D946-4CED-A23B-0A2BEAEF702B

Q40118659-CEE922BC-1275-4B57-B297-AACC6942827E

Q40118659-D2E92602-78C7-48E2-8743-AD3233CBB1D2

Q40118659-E372B371-6A7B-475C-B685-5FC093784284

P2860

Q40118659-16145384-47BA-4A37-957E-842558BE97D2

Q40118659-29EC7EB4-6517-4073-B7F2-8FB241F70ABA

Q40118659-2FDE6A62-A761-4641-B72B-EF3A20ABDAED

Q40118659-3B8744ED-5416-47F7-A71B-BFBE5FF0ADB9

Q40118659-41108E98-8F27-43C6-9A76-3854EDFA0CFA

Q40118659-4BC188A8-3500-4121-8BA0-1646CB2D0E0C

Q40118659-4F6EBF24-456B-4AC6-9AB7-87CA54A9F2C5

Q40118659-4FFE635B-660E-4DB9-9DEF-FF100BD2301B

Q40118659-604C35D6-5979-4F43-92DB-FEA41DDB93B4

Q40118659-62823AE3-ED2B-413C-BB3A-443FD47A9402

P304

Q40118659-CB3DE89C-232C-4322-ABC9-1937282D7588

P31

Q40118659-6AECA87A-4250-4BFD-9064-54CAA3EFE6AA

P356

Q40118659-19F5C4E0-36E5-4B15-9F8C-CF99C8F81A98

P433

Q40118659-C7136677-AD22-4113-A8BF-08CD263D63F9

P478

Q40118659-DB83E4CC-D34D-4C9A-A71A-D88EF5C3DF28

P577

Q40118659-4B8BFAFB-67BF-4F5E-A484-762301E6A962

P5875

Q40118659-FB92654A-0FED-40D9-B37E-960323016044

P698

Q40118659-0A3397C3-DB3B-4621-9877-E1BF391B0459

P921

Q40118659-C3F244D2-E855-4C3F-96FA-32A3127558B4

P356

AJPLUNG.00108.2007

P1433

American Journal of Physiology - Lung Cellular and Molecular Physiology

P1476

Pharmacological properties of ...... piratory inflammatory disease.

@en

P2093

David W Gray

http://www.w3.org/2001/XMLSchema#string

Iain J Uings

http://www.w3.org/2001/XMLSchema#string

Joyce L Matthews

http://www.w3.org/2001/XMLSchema#string

Keith Biggadike

http://www.w3.org/2001/XMLSchema#string

Mark Salter

http://www.w3.org/2001/XMLSchema#string

Michael R West

http://www.w3.org/2001/XMLSchema#string

Michael V Haase

http://www.w3.org/2001/XMLSchema#string

Stuart N Farrow

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition

Antiinflammatory action of glucocorticoids--new mechanisms for old drugs

Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy.

The IKK NF-kappa B system: a treasure trove for drug development.

Structure and function of the glucocorticoid receptor ligand binding domain.

Molecular mechanisms and cellular effects of glucocorticosteroids.

Glucocorticoid and mineralocorticoid cross-talk with progesterone receptor to induce focal adhesion and growth inhibition in breast cancer cells.

Maintenance of the epithelial barrier in a bronchial epithelial cell line is dependent on functional E-cadherin local to the tight junctions.

Loss of epithelial integrity resulting from E-cadherin dysfunction predisposes airway epithelial cells to adenoviral infection.

Transforming growth factor-alpha abrogates glucocorticoid-stimulated tight junction formation and growth suppression in rat mammary epithelial tumor cells.

P304

L660-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPLUNG.00108.2007

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

293

http://www.w3.org/2001/XMLSchema#string

P577

2007-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6262131

http://www.w3.org/2001/XMLSchema#string

P698

17575011

http://www.w3.org/2001/XMLSchema#string

P921